Sort by 'listens'
Transplants and Risk Adapted Maintenance in Myeloma Treatment
The treatment paradigm for myeloma patients has changed in the last decade with important advancements such as proteasome inhibitors, IMiDS, antibodies and risk-adapted maintenance. How a patient responds to therapy can be used to determine how long the maintenance or…
Dana Farber’s Dr. Richardson on Transplants in Myeloma
To Transplant or Not To Transplant: Hear it from world renowned myeloma expert, Dr. Paul Richardson of Harvard's Dana Farber Cancer Center.
Myeloma ASH 2013 Review
Tune in to get interesting myeloma updates - 2013 ASH conference, from Myeloma Support Group leaders and myeloma advocates, Gary Petersen, Pat Killingsworth, Jack Aiello, and Cynthia Chmielewski.
Nanotech as Prevention by Nanotronics Imaging & MetaMed
In this show we discuss Nanotechnology as Prevention with Dr. Mathew Putman, CEO, Nanotronics Imaging, Andrew Rettek from MetaMed, and Dr. Georges Sylvestre from Weill Cornell.
Multiple Myeloma: An Insight into Early Intervention and Personalized Therapies
Myeloma patients are definitely living longer. A decade ago the median survival was 3 to 4 years, while now it is in the range of 8 to 10 years. With all the new drugs and treatments that have been approved,…